進行性心不全患者の機械的循環支援後の電気生理学的変化
J D Harding1, V Piacentino, J P Gaughan
1Cardiovascular Research Group, Temple University School of Medicine, Philadelphia, PA, USA.
Circulation
|September 12, 2001
まとめ
左心室補助器 (LVAD) のインプラントは,心不全患者の心室伝導と再極化を急激に変化させます. 持続的なLVADサポートは,電気生理学的改造を逆転させ,心臓の機能を改善します.
科学分野:
- 心臓病学 心臓病学
- 電気生理学 電気生理学
- 医療機器 医療機器について
背景:
- 左心室補助装置 (LVAD) の機械的循環支援は,心筋の構造と機能を変化させます.
- LVAD後の電気生理学的変化を理解することは,心不全の管理に不可欠です.
研究 の 目的:
- 失敗する人間の心臓にLVADの埋め込み後の心室伝導と再極化の変化を調査する.
- 心臓の電気生理学に対するヘモダイナミック・アンロードの影響を評価する.
主な方法:
- LVADの埋め込み前と後の23人の心不全患者の12導電心電図 (ECG) を分析した.
- ECGの変化を冠動脈バイパス移植 (CABG) を受けた22人の患者と比較した.
- 移植された心臓におけるミオサイトの研究と相関するEKGの発見.
主要な成果:
- LVADを配置すると,QRSの持続時間が急激に減り,QTの持続時間とQTc間隔が増加しました.
- これらの即時の変化は,CABG患者では観察されなかった.
- 持続的なLVADサポートにより,QTc間隔が著しく短縮され,ミオサイトにおけるアクションポテンシャル期間が短縮されたことが確認されました.
結論:
- LVAD後の急性EKGの変化は,衰弱した心臓におけるQRSとQTの持続時間の負荷依存性を強調する.
- 遅れたQTcとアクションポテンシャル持続時間の減少は,電気生理学的改造の逆転を示しています.
- アクションポテンシャル期間が短縮されることは,LVADサポート後の細胞収縮性の改善に寄与する可能性があります.
関連する概念動画
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


